Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Sep
10
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo